Literature DB >> 10767887

The neuroleptic malignant and serotonin syndromes.

J R Carbone1.   

Abstract

The neuroleptic malignant syndrome and the serotonin syndrome share many clinical features and may exist on a spectrum of the same disorder. The neuroleptic malignant syndrome, however, is an idiosyncratic drug reaction, whereas the serotonin syndrome is an effect of drug toxicity. Both syndromes present with varying degrees of mental status changes and autonomic instability. In general, patients with the neuroleptic malignant syndrome have higher fevers and pronounced extrapyramidal signs with muscle rigidity, whereas patients with the serotonin syndrome have lower fevers, more gastrointestinal dysfunction, and myoclonus. Treatment for both syndromes consists of removing the offending agent and providing intensive supportive care. Syndrome-specific therapies are controversial.

Entities:  

Mesh:

Year:  2000        PMID: 10767887     DOI: 10.1016/s0733-8627(05)70127-9

Source DB:  PubMed          Journal:  Emerg Med Clin North Am        ISSN: 0733-8627            Impact factor:   2.264


  13 in total

Review 1.  Serotonin syndrome: a brief review.

Authors:  Philippe Birmes; Dominique Coppin; Laurent Schmitt; Dominique Lauque
Journal:  CMAJ       Date:  2003-05-27       Impact factor: 8.262

Review 2.  Serotonin toxicity: a short review of the literature and two case reports involving citalopram.

Authors:  G Talarico; G Tosto; S Pietracupa; E Piacentini; M Canevelli; G L Lenzi; G Bruno
Journal:  Neurol Sci       Date:  2011-04-14       Impact factor: 3.307

3.  Early detection of an atypical presentation of neuroleptic malignant syndrome: A case report.

Authors:  P Brittany Vickery; Lindsy Meadowcraft; Stephen B Vickery
Journal:  Ment Health Clin       Date:  2018-03-23

4.  Parkinsonism-hyperpyrexia syndrome: Broadening our differential diagnosis in the ICU.

Authors:  Sara Hocker; Daniel L Kenney; Kannan Ramar
Journal:  Neurol Clin Pract       Date:  2013-12

5.  A patient with encephalitis associated with NMDA receptor antibodies.

Authors:  Lauren H Sansing; Erdem Tüzün; Melissa W Ko; Jennifer Baccon; David R Lynch; Josep Dalmau
Journal:  Nat Clin Pract Neurol       Date:  2007-05

6.  Olanzapine-Induced Malignant Neuroleptic Syndrome.

Authors:  Tuba Berra Sarıtaş; Barış Çankaya; Alper Yosunkaya
Journal:  Turk J Anaesthesiol Reanim       Date:  2014-07-09

7.  The toxicology and comorbidities of fatal cases involving quetiapine.

Authors:  Jennifer L Pilgrim; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2013-02-09       Impact factor: 2.007

Review 8.  An approach to iatrogenic deaths.

Authors:  Angela R McGuire; Maura E DeJoseph; James R Gill
Journal:  Forensic Sci Med Pathol       Date:  2016-01-28       Impact factor: 2.007

9.  Neuroleptic malignant syndrome caused by a combination of carbamazepine and amitriptyline.

Authors:  A Bruce Janati; Naif Alghasab; Aboubaker Osman
Journal:  Case Rep Neurol Med       Date:  2012-07-24

Review 10.  Bench-to-bedside review: mechanisms and management of hyperthermia due to toxicity.

Authors:  Florian Eyer; Thomas Zilker
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.